The Asia Pacific Arteriovenous Fistula Devices Market would witness market growth of 8.0% CAGR during the forecast period (2023-2030).
Blood clots may develop as a result of an arteriovenous fistula in the legs. Deep vein thrombosis, sometimes known as DVT, can result from blood clots in the legs. When a blood clot enters the lungs (a pulmonary embolism), deep vein thrombosis (DVT) poses a serious risk to life. The location of the fistula will determine if a stroke occurs. Leg pain brought on by a blood flow problem (claudication). Leg pain may result from a blocked blood supply to muscles from an arteriovenous fistula. Stomach and intestinal hemorrhage could result from untreated arteriovenous fistulas.
Governments in developing nations like China, Taiwan, India, and Indonesia, among others, are implementing policies to entice foreign investors to the corresponding industrial sectors by reducing trade taxes and levies in order to create more jobs. Key market participants for AVF devices are also actively pursuing strategic initiatives to stimulate market expansion. By improving patient outcomes and lowering problems related to AVF treatments, these technical developments play a critical role in fueling market expansion. As a result, there is an increase in demand for novel AVF devices, which is opportunistic for the market.
Rapid aging in the Asia Pacific has made the region the leader of one of the most significant worldwide demographic trends, owing to increased life expectancies and declining fertility rates. By the year 2050, one person in every four living in Asia and the Pacific will be over the age of 60. Not only is dialysis free but there are also no price variances for patients based on the type of dialysis. In Japan, everyone is entitled to free national health insurance. For full access to dialysis, including all necessary drugs and consumables, each patient pays a copayment of up to 10,000 ($90) per month. Thus, the region presents lucrative growth prospects for the market.
The China market dominated the Asia Pacific Arteriovenous Fistula Devices Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $35.2 million by 2030. The Japan market is estimated to grow at CAGR of 7.3% during (2023 - 2030). Additionally, The India market would showcase a CAGR of 8.6% during (2023 - 2030).
Based on End-use, the market is segmented into Hospitals, Ambulatory Surgical Centers and Dialysis Centers. Based on Type, the market is segmented into AVF Creation Devices (Surgical Instruments, Vascular Grafts, Angioplasty Balloons and Others), AVF Monitoring Devices (Doppler Ultrasound, Pressure Monitoring Systems, and Others) and AVF Maintenance Devices (Central Venous Catheters, Stents and Others). Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
Free Valuable Insights: The Worldwide Arteriovenous Fistula Devices Market is Projected to reach USD 521.9 Million by 2030, at a CAGR of 6.9%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Medtronic PLC, Becton, Dickinson and Company, Teleflex, Inc., Fresenius Medical Care AG & Co. KGaA. (Fresenius SE & Co. KGaA), B. Braun Melsungen AG, Poly Medicure Ltd., Asahi Kasei Corporation, Laminate Medical Technologies Ltd., Cook Medical, Inc. (Cook Group), and Boston Scientific Corporation
By End-use
By Type
By Country
Unique Offerings Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
